14 unchanged sentences
October 2 through October 29, 2023
+Added: 12,222 $ 32.93 — $ 3,292,882,444
October 30 through November 30, 2023
+Added: 25,825 $ 29.95 — $ 3,292,882,444
December 1 through December 31, 2023
+Added: 14,449 $ 28.58 — $ 3,292,882,444
Total 52,496 $ 30.26 —
(a) See Note 12 .
−Removed: 2022 Form 10-K 24
(b) Represents (i) 49,685 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,811 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.
2 unchanged sentences
and European-based pharmaceutical companies, which are:
−Removed: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Roche Holding AG and Sanofi SA, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).
+Added: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi SA, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).
Five Year Performance
4 unchanged sentences
DRG Index $100.0 $118.4 $128.7 $158.8 $171.1 $184.3
+Added: 2023 Form 10-K
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.